Form 4: Lineage Cell Therapeutics Director Michael Mulroy Granted 75,000 Stock Options

Lineage Cell Therapeutics, Inc. Director Michael H. Mulroy was granted 75,000 stock options with an exercise price of $0.8977, vesting by July 2026.

Summary

• Michael H. Mulroy, a Director of Lineage Cell Therapeutics, Inc. (LCTX), was granted 75,000 stock options.
• The stock options have an exercise price of $0.8977 per share.
• The grant date for these options was July 1, 2025.
• The options will expire on July 1, 2035.
• Vesting will occur on the earlier of July 1, 2026, and the date of the issuer's next annual meeting of shareholders, contingent on continuous service with the issuer.
• Following this transaction, Michael H. Mulroy beneficially owns 75,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a common practice to align management interests with shareholder value, indicating continued commitment and incentivizing long-term performance.

Positives

• The grant of 75,000 stock options to Director Michael H. Mulroy aligns his interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $0.8977 provides a clear benchmark for future stock performance relative to the grant date.

Future Outlook

The stock options are subject to vesting on the earlier of July 1, 2026, or the next annual meeting, contingent on the reporting person's continuous service, indicating an expectation of continued tenure.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors in the biotechnology and cell therapy industry to align their interests with long-term company performance and shareholder value.

Related Party Transactions

• Grant of 75,000 stock options to Michael H. Mulroy, a Director of Lineage Cell Therapeutics, Inc., with an exercise price of $0.8977.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns management's long-term interests with shareholder value, potentially leading to improved company performance.

Next Steps

• Vesting of the 75,000 stock options on the earlier of July 1, 2026, or the date of the issuer's next annual meeting of shareholders.

Key Dates

Keywords

Lineage Cell Therapeutics, LCTX, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Michael H. Mulroy